Philippines - English - FDA (Food And Drug Administration)

the generics pharmacy, inc - co-amoxiclav - powder for suspension - 400 mg/57 ml

Philippines - English - FDA (Food And Drug Administration)

nelpa lifesciences, inc.; distributor: nelpa lifesciences, inc. - co-amoxiclav - powder for oral suspension - 250mg/62.5mg per 5ml

United States - English - NLM (National Library of Medicine)

takeda pharmaceuticals america, inc. - lisdexamfetamine dimesylate (unii: sjt761gegs) (lisdexamfetamine - unii:h645gul8kj) - lisdexamfetamine dimesylate 10 mg - vyvanse® is indicated for the treatment of: - attention deficit hyperactivity disorder (adhd) in adults and pediatric patients 6 years and older [see clinical studies (14.1)] - moderate to severe binge eating disorder (bed) in adults [see clinical studies (14.2)] . limitations of use: - pediatric patients with adhd younger than 6 years of age experienced more long-term weight loss than patients 6 years and older [see use in specific populations (8.4)] . - vyvanse is not indicated or recommended for weight loss. use of other sympathomimetic drugs for weight loss has been associated with serious cardiovascular adverse events. the safety and effectiveness of vyvanse for the treatment of obesity have not been established [see warnings and precautions (5.2)] . vyvanse is contraindicated in patients with: - known hypersensitivity to amphetamine products or other ingredients of vyvanse. anaphylactic reactions, stevens-johnson syndrome, angioedema, and urticaria have been observed in postmarketing reports [see adve

United States - English - NLM (National Library of Medicine)

state of florida doh central pharmacy - doxazosin mesylate (unii: 86p6pqk0mu) (doxazosin - unii:nw1291f1w8) - doxazosin 4 mg - doxazosin mesylate is indicated for the treatment of both the urinary outflow obstruction and obstructive and irritative symptoms associated with bph: obstructive symptoms (hesitation, intermittency, dribbling, weak urinary stream, incomplete emptying of the bladder) and irritative symptoms (nocturia, daytime frequency, urgency, burning). doxazosin mesylate may be used in all bph patients whether hypertensive or normotensive. in patients with hypertension and bph, both conditions were effectively treated with doxazosin mesylate monotherapy. doxazosin mesylate provides rapid improvement in symptoms and urinary flow rate in 66 to 71% of patients. sustained improvements with doxazosin mesylate were seen in patients treated for up to 14 weeks in double-blind studies and up to 2 years in open-label studies. doxazosin mesylate is also indicated for the treatment of hypertension. doxazosin mesylate may be used alone or in combination with diuretics, beta-adrenergic blocking agents, calcium channel blockers, or angio

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

uhs essential health (malaysia) sdn. bhd. - co-enzyme q-10; alpha lipoic acid -

Zimbabwe - English - Medicines Control Authority

bell lifestyle zimbabwe pvt ltd - co-enzyme q10; vitamin a; vitamin e - capsule; oral - 60mg; 180iu; 50iu

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

jamjoom pharmaceuticals co. ltd., saudi arabia - capsule, soft - 50 mg - co enzyme q10, ubidecarenone

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

jamjoom pharmaceuticals co. ltd., saudi arabia - capsule, soft - 100 mg - co enzyme q10, ubidecarenone

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

jamjoom pharmaceuticals co. ltd., saudi arabia - capsule, soft - 200 mg - co enzyme q10, ubidecarenone

Philippines - English - FDA (Food And Drug Administration)

gamot philippines, inc.; importer: n/a; distributor: pharma dynamic, inc. - co-avox - film-coated tablet - 625mg